Flutoprazepam
From Wikipedia, the free encyclopedia
 |
|
|
Flutoprazepam
|
|
| Systematic (IUPAC) name | |
| 7-chloro-1-cyclopropylmethyl-1,3-dihydro-5-(2-fluorophenyl)-2H-1,4-benzodiazepin-2-one | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C19H16ClFN2O |
| Mol. mass | 342.795 |
| Pharmacokinetic data | |
| Bioavailability | 80-90% |
| Metabolism | Hepatic |
| Half life | 60-90 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
X(US) |
| Legal status |
Schedule IV(US) |
| Routes | Oral, Intravenous |
Flutoprazepam (Restas, KB-509) is a drug which is a benzodiazepine derivative. It was invented in Japan in 1972, and its medical use remains mostly confined to that country. Its muscle relaxant properties are approximately equivalent to those of diazepam - however, it has powerful sedative, hypnotic, anxiolytic and anticonvulsant effects and is around four times more potent by weight compared to diazepam. [1] It is longer acting than diazepam due to its long-acting active metabolites,[2] which contribute significantly to its effects.[3]
Flutoprazepam is used for the treatment of insomnia and may also be used for treating stomach ulcers.[4]
Abuse of benzodiazepines in Japan is extremely common, with flutoprazepam being one of the most commonly abused, along with the benzodiazepines of abuse nimetazepam and temazepam. As of late 2007, the Japanese government is considering placing nimetazepam and temazepam into a more restrictive drug schedule. It is unknown as of yet whether flutoprazepam will be subject to the same controls. Triazolam, oxazepam, and nitrazepam are also very common benzodiazepines of abuse in Japan.[citation needed]
[edit] References
- ^ Sukamoto T, Aikawa K, Itoh K, Nose T. Psychopharmacological and general pharmacological studies of 7-chloro-1-cyclopropylmethyl-1, 3-dihydro-5-(2-fluorophenyl)-2H-1, 4-benzodiazepin-2-one (KB-509). Nippon Yakurigaku Zasshi. 1980 Sep;76(6):447-68. (Japanese).
- ^ Ueki S, Sukamoto T, Watanabe S, Yamamoto T, Kataoka Y, Shibata S, Suwandi D, Shibata K, Takano M, Sato Y. Behavioral effects of flutoprazepam (KB-509) and its metabolites. Nippon Yakurigaku Zasshi. 1982 Jul;80(1):15-30. (Japanese).
- ^ Barzaghi N, Leone L, Monteleone M, Tomasini G, Perucca E. Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects. European Journal of Drug Metabolism and Pharmacokinetics. 1989 Oct-Dec;14(4):293-8.
- ^ Fukuda T, Itoh K, Nose T. Antiulcerogenic action of 7-chloro-1-cyclopropylmethyl-1,3-dihydro-5-(2-fluorophenyl)-2H-1,4-benzodiazepin-2-one (KB-509), a new benzodiazepine derivative. Nippon Yakurigaku Zasshi. 1981 Mar;77(3):273-80. (Japanese).
|
|||||||||||||||||||||||||||||
